Eli Lilly and Co. has been granted a patent for an automatic injection device featuring a syringe carrier with interlocking parts and a retraction assembly. The design includes a cushion to support the syringe and a follower mechanism for medication expulsion, enhancing the device’s functionality and stability. GlobalData’s report on Eli Lilly and Co gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Eli Lilly and Co, Cancer treatment biomarkers was a key innovation area identified from patents. Eli Lilly and Co's grant share as of June 2024 was 55%. Grant share is based on the ratio of number of grants to total number of patents.
Automatic medication injection device with syringe carrier assembly
The granted patent US12042634B2 describes a medication injection device designed to enhance the stability and functionality of syringe-based medication delivery. The device features a housing with a proximal and distal end, housing a syringe that includes a needle, syringe body, syringe flange, and a plunger. A key component of the device is the syringe carrier, which consists of two interlockable parts that fully encase the syringe flange. Each part of the carrier is equipped with a cushion that provides support to the syringe flange while also incorporating multiple cushion protrusions. These protrusions are strategically designed to contact the syringe body beneath the flange, ensuring proper centering and stability during operation.
Additionally, the device includes a shuttle mechanism that facilitates the movement of the syringe within the housing, allowing the needle to extend or retract as needed. The shuttle is engaged during the proximal movement, and a follower mechanism is included to manage the interaction between the plunger and the shuttle. The design incorporates features such as a plunger spring and a biasing member to ensure smooth operation. The patent outlines various configurations and materials used in the construction of the device, emphasizing the importance of material hardness and compressibility in the cushions and protrusions to optimize performance. Overall, the invention aims to improve the user experience and efficacy of medication delivery through enhanced structural support and operational mechanics.
To know more about GlobalData’s detailed insights on Eli Lilly and Co, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
